Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Cinnarizine

    go.drugbank.com/drugs/DB00568
    ApprovedInvestigational

    Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting … centre of the hypothalamus.

  2. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal

  3. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. … -2a for the treatment of Hepatitis C [A19593].

  4. Drug

    Cefotaxime

    go.drugbank.com/drugs/DB00493
    ApprovedInvestigational

    In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

    Products: CLAFORAN 0.5 G IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, CLAFORAN 2G/40 ML IM/IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ
  5. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  6. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.

  7. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [A254387] The antibody component of mirvetuximab soravtansine-gynx binds to FRα, a receptor overexpressed on the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative … [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and DM4 is released inside the cell.

  8. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [A260256] DMD tends to be more prevalent in males. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  9. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    It is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  10. Drug

    Alosetron

    go.drugbank.com/drugs/DB00969
    ApprovedWithdrawn

    In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

    Categories: Serotonin Receptor Antagonists, Serotonin 3 Receptor Antagonists